Recombinant zoster vaccine — flat >90% efficacy across every age group
Latent varicella-zoster virus reactivates as immunity naturally declines with age.
T-cell immunity to VZV fades gradually after childhood chickenpox.
Waning cell-mediated immunity lets latent virus reactivate in sensory ganglia.
Cell-mediated immunity, not antibody level, is the key barrier against reactivation.
Adults over 50 and immunocompromised patients face the steepest risk rise.
Complications include postherpetic neuralgia, vision loss, and hospitalization.
Older live-attenuated shingles vaccines lost effectiveness in the oldest patients.
A vaccine strategy independent of age-related immune decline was needed.
A single recombinant glycoprotein E antigen, paired with adjuvant, primes the immune system.
Glycoprotein E is the most abundant VZV surface protein and a dominant immune target.
It anchors both antibody and T-cell recognition of the virus.
AS01B combines MPL and QS-21 in a liposome to strongly stimulate innate immunity.
This adjuvant is central to overcoming age-related immune decline.
AS01B, not the antigen alone, is what drives strong response in older adults.
Antigen-presenting cells process gE and activate naive T and B cells.
A measurable but partial immune response builds over the following weeks.
A second dose 2–6 months later converts a primed response into durable memory.
A single dose leaves immune memory incomplete and less durable.
The booster recalls and expands memory B and T cells sharply.
Germinal center reactions mature antibody affinity after the second exposure.
Central memory T cells expand, extending years of protection.
The two-dose series is what makes protection durable, not just initial titer.
ZOE-50 and ZOE-70 trials established the 2–6 month interval as optimal.
Shorter or longer intervals were tested but this window performed best.
Antibody titers and T-cell frequency reach their highest post-vaccination levels.
Anti-gE antibody concentration and gE-specific CD4+ T cells are both tracked.
Both rise sharply and peak roughly one month after dose 2.
The AS01B adjuvant compensates for the age-related decline in raw immune reserve.
Peak responses in 70+ and 80+ groups closely track younger adults.
Peak magnitude stays comparable across ages — the core efficacy-by-age finding.
High peak titer and T-cell counts translate directly into trial-measured efficacy.
This peak is the immunologic basis for the >90% efficacy figure.
Efficacy remains flat above 90%, even years later and in the oldest recipients.
Unlike most vaccines, efficacy does not decline meaningfully with age.
This distinguishes Shingrix from earlier live-attenuated shingles vaccines.
The oldest age group protects nearly as well as the youngest — a rare vaccine trait.
Strong adjuvant-driven priming leaves a durable memory pool despite immunosenescence.
Memory cells decline slowly rather than immunity never fully forming.
Recommended for adults 50+ regardless of prior shingles or chickenpox history.
Broad, age-independent efficacy simplifies vaccination guidance globally.